蒽环类药物（anthracyclines）的应用在肿瘤治疗的历史长河中具有里程碑式的意义，其应用范围广泛。尽管在靶向治疗与免疫治疗等新兴疗法日新月异的当下，蒽环类药物依然在多种实体肿瘤及血液恶性肿瘤治疗中发挥着重要作用。那么，蒽环类药物具体涵盖了哪些 ...

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute ...

As of the June 21 data cutoff, the abstracts continue to support a potential best-in-class safety and tolerability profile ...

Patients received induction chemotherapy with oblimersen, cytarabine and daunorubicin. Further doses of oblimersen and high-dose cytarabine were administered as consolidation treatment in the ...

Midostaurin is a kinase inhibitor prescribed as a combination therapy with cytarabine and daunorubicin for treating adult patients with acute myeloid leukemia who are detected as FLT3 mutation ...

Nanoparticles have once again reached the spotlight, this time as a critical tool to combat the spread of covid-19. In this ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...

Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] Technology appraisal guidance ...

(Radiology)Multiple recent market withdrawals of drugs that received FDA accelerated approvals have raised concern about the ...

She initially received oral tretinoin (Vesanoid) followed by daunorubicin on days 1 through 3 and cytarabine on days 1 to 5 (planned treatment is to receive cytarabine for 2 more doses).

Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –– ...